The percentages of patients treated with MMX mesalazine , 2.4 or 4.8 g/day , in clinical and endoscopic remission at week 8 were similar and significantly ( P < 0.05 ) greater than placebo in subgroups stratified by disease extent , disease severity and gender and among patients not previously receiving low-dose 5-aminosalicylic acid .
